Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

TearCare MGX™ System With and Without Warming Hold

NCT: NCT07365735 · ACTIVE_NOT_RECRUITING

NCT IDNCT07365735
StatusACTIVE_NOT_RECRUITING
Start Date2026-03-17
Completion2026-05

Brief Summary

TearCare is an office-based thermal therapeutic eyelid technology cleared by the US Food and Drug Administration for the treatment of evaporative dry eye disease due to meibomian gland dysfunction. In this randomized study, TearCare procedures using the TearCare MGX System (study device) with the extended Warming hold feature will be compared with TearCare procedures using the TearCare MGX System without the Warming hold (control group).

Frequently Asked Questions

What is TearCare MGX™ System With and Without Warming Hold?

TearCare MGX™ System With and Without Warming Hold is a clinical trial registered under NCT07365735. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT07365735?

The current status of NCT07365735 (TearCare MGX™ System With and Without Warming Hold) is: ACTIVE_NOT_RECRUITING.

When did TearCare MGX™ System With and Without Warming Hold start?

TearCare MGX™ System With and Without Warming Hold started on 2026-03-17.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.